Inicio › Linfoma difuso de células B grandes › Nueva York
Ensayos clínicos de Linfoma difuso de células B grandes en Nueva York
29 estudios sobre Linfoma difuso de células B grandes buscan participantes en Nueva York.
Ciudades en Nueva York
Texto oficial del estudio (inglés)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- New York Oncology Hematology, P.C. ( Site 0129), Albany
- Icahn School of Medicine at Mount Sinai ( Site 0164), New York
- New York Cancer and Blood Specialists ( Site 9000), Shirley
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Roswell Park Cancer Institute ( Site 0192), Buffalo
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0208), Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108), New York
- y 2 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT06890884Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT05272384Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- New York Oncology Hematology, P.C., Albany
- Hematology Oncology Associates of Central New York, East Syracuse
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06806033Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Roswell Park Cancer Institute, Buffalo
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06649812A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Stony Brook University Hospital, Stony Brook
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07101328A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Roswell Park Comprehensive Cancer Center, Buffalo
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07188558A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Columbia University, New York
- University of Rochester, Rochester
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07226843A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- y 1 más
ReclutandoFase 2
Edades de 65 a 80 · Todos los sexos · Actualizado el 30 oct 2026 · NCT06765317Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
ReclutandoFase 1/2
6 Months – 25 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York
- University of Rochester Medical Center, Rochester
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06500273Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- University of Rochester, Rochester
- Wilmot Cancer Institute at Webster, Webster
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT05890352Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
- Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT07725406Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06533579Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
- New York Medical College, Valhalla
ReclutandoFase 2
Edades de 3 a 31 · Todos los sexos · Actualizado el 23 oct 2026 · NCT02393157Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
- University of Rochester, Rochester
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT05633615Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT05940272A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Memorial Sloan Kettering Cancer Center, New York
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 oct 2026 · NCT07195916A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Roswell Park Comprehensive Cancer Center, Buffalo
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- y 1 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT05006716Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
- Roswell Park Cancer Institute, Buffalo
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06863402Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Roswell Park Comprehensive Cancer Center, Buffalo
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, The Bronx
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT05826535DALY II USA/ MB-CART2019.1 for DLBCL
- Memorial Sloan Kettering Cancer Center, New York
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT04792489Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center - Moses Campus, The Bronx
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT05077527Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- New York Medical Center, Valhalla
ReclutandoFase 1/2
Edades de 12 a 70 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04491370ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
- Columbia University, New York
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 ene 2026 · NCT06693830A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 dic 2025 · NCT06736613A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
- Wilmot Cancer Institute, Rochester
ReclutandoFase 2
Edades de 70 en adelante · Todos los sexos · Actualizado el 20 oct 2025 · NCT06828991Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Memorial Sloan Kettering Cancer Center, New York
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 sept 2024 · NCT06238648De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.